Art Of The Deal: Negotiating With Prospective Employers

Sometimes, negotiating with a prospective employer is easy. "In fact, I wrote my own ticket," says K.C. Nicolaou, a chemist lured from the University of Pennsylvania after being courted by the Scripps Research Institute, La Jolla, Calif., and the University of California, San Diego, for a dual appointment. "Essentially, [Scripps and UC-San Diego] did exactly what I asked them to do." It didn't hurt his position, he recalls, that "at the same time I was recruited by Yale." Clearly in the catbird

Written byScott Huler
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Clearly in the catbird seat, Nicolaou negotiated from a position of strength and chose a dream situation: two new labs, colleagues he respected at UC-San Diego, the opportunity to hire colleagues he wanted at Scripps, and, virtually, carte blanche to determine the direction of a new chemistry department at Scripps--on top, of course, of salary and benefits he describes as "very generous." Not bad.

Yet hammering out an agreement doesn't always go so smoothly; even impressive credentials and generous offers don't guarantee a positive end to a negotiation. Biosciences placement consultant Erwin Posner of Southfield, Mich., recalls a Johns Hopkins University professor he recruited for a position with a "deep-pocketed" major research firm. The scientist, late in negotiations, botched the deal by implying that the offer was only his second choice, says Posner: "He told them a pending [National Institutes of Health] grant would supersede their offer if it came ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies